{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:33:31Z","timestamp":1793741611402,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ParkinsonFonds Deutschland,Germany Andre Leysen Ulran Foundation, Belgium Stichting ParkinsonFonds, The Netherlands","id":[{"id":"https:\/\/ror.org\/04550kp61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"ParkinsonFonds Deutschland, Germany"},{"name":"Stichting ParkinsonFonds The Netherlands","id":[{"id":"https:\/\/ror.org\/04550kp61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"JPB Foundation, USA","id":[{"id":"https:\/\/ror.org\/05nzwyq50","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Isolated REM Sleep Behavior Disorder (iRBD) is considered a prodrome of Parkinson\u2019s disease (PD). We investigate whether the potentially disease-modifying compound acetyl-\n                    <jats:sc>DL<\/jats:sc>\n                    -leucine (ADLL; 5\u2009g\/d) has an effect on prodromal PD progression in 2 iRBD-patients. Outcome parameters are RBD-severity sum-score (RBD-SS-3), dopamine-transporter single-photon emission computerized tomography (DAT-SPECT) and metabolic \u201cParkinson-Disease-related-Pattern (PDRP)\u201d-z-score in\n                    <jats:sup>18<\/jats:sup>\n                    F-fluorodeoxyglucose positron emission tomography (FDG-PET). After 3 weeks ADLL-treatment, the RBD-SS-3 drops markedly in both patients and remains reduced for &gt;18 months of ADLL-treatment. In patient 1 (female), the DAT-SPECT putaminal binding ratio (PBR) decreases in the 5 years pretreatment from normal (1.88) to pathological (1.22) and the patient\u2019s FDG-PET-PDRP-z-score rises from 1.72 to 3.28 (pathological). After 22 months of ADLL-treatment, the DAT-SPECT-PBR increases to 1.67 and the FDG-PET-PDRP-z-score stabilizes at 3.18. Similar results are seen in patient 2 (male): his DAT-SPECT-PBR rises from a pretreatment value of 1.42 to 1.72 (close to normal) and the FDG-PET-PDRP-z-score decreases from 1.02 to 0.30 after 18 months of ADLL-treatment. These results support exploration of whether ADLL may have disease-modifying properties in prodromal PD.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-51502-7","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T07:02:21Z","timestamp":1725260541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern\u2014case reports"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-8166","authenticated-orcid":false,"given":"Wolfgang H.","family":"Oertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Janzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"Henrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni F.","family":"Geibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Sittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne K.","family":"Meles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Booij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-5225","authenticated-orcid":false,"given":"D. James","family":"Surmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-2279","authenticated-orcid":false,"given":"Michael","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"51502_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.26077","volume":"30","author":"C Pont-Sunyer","year":"2015","unstructured":"Pont-Sunyer, C. et al. The onset of nonmotor symptoms in Parkinson\u2019s disease (the ONSET PD study). Mov. Disord. 30, 229\u2013237 (2015).","journal-title":"Mov. Disord."},{"key":"51502_CR2","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/mdc3.13908","volume":"10","author":"F Sixel-D\u00f6ring","year":"2023","unstructured":"Sixel-D\u00f6ring, F. et al. The increasing prevalence of REM sleep behavior disorder with Parkinson\u2019s disease progression: a polysomnography-supported study. Mov. Disord. Clin. Pr. 10, 1769\u20131776 (2023).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"51502_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma, R. B. et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142, 744\u2013759 (2019).","journal-title":"Brain"},{"key":"51502_CR4","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.3233\/JPD-223201","volume":"12","author":"A Janzen","year":"2022","unstructured":"Janzen, A. et al. Progressive olfactory impairment and cardiac sympathetic denervation in REM sleep behavior disorder. J. Parkinsons Dis. 12, 1921\u20131935 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"51502_CR5","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s00415-021-10625-3","volume":"268","author":"T Fields","year":"2021","unstructured":"Fields, T., Schoser, B., Oertel, W. & Strupp, M. Acetyl-DL-leucine improves restless legs syndrome: a case report. J. Neurol. 268, 2595\u20132596 (2021).","journal-title":"J. Neurol."},{"key":"51502_CR6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/jcm9041050","volume":"9","author":"E Kaya","year":"2020","unstructured":"Kaya, E. et al. Beneficial effects of acetyl-DL-leucine (ADLL) in a mouse model of Sandhoff disease. J. Clin. Med. 9, 1050 (2020).","journal-title":"J. Clin. Med."},{"key":"51502_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa148","volume":"3","author":"E Kaya","year":"2021","unstructured":"Kaya, E. et al. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 3, fcaa148 (2021).","journal-title":"Brain Commun."},{"key":"51502_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2310151","volume":"390","author":"T Bremova-Ertl","year":"2024","unstructured":"Bremova-Ertl, T. et al. Trial of N-acetyl-l-leucine in Niemann-Pick disease type C. New Engl. J. Med. 390, 421\u2013431 (2024).","journal-title":"New Engl. J. Med."},{"key":"51502_CR9","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00415-021-10717-0","volume":"269","author":"T Bremova-Ertl","year":"2022","unstructured":"Bremova-Ertl, T. et al. Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C. J. Neurol. 269, 1651\u20131662 (2022).","journal-title":"J. Neurol."},{"key":"51502_CR10","doi-asserted-by":"publisher","first-page":"e1072","DOI":"10.1212\/WNL.0000000000201660","volume":"100","author":"K Martakis","year":"2023","unstructured":"Martakis, K. et al. Efficacy and safety of N-acetyl-l-leucine in children and adults with GM2 gangliosidoses. Neurology 100, e1072\u2013e1083 (2023).","journal-title":"Neurology"},{"key":"51502_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad364","author":"T Payne","year":"2023","unstructured":"Payne, T. et al. Multimodal assessment of mitochondrial function in Parkinson\u2019s disease. Brain 147, 267\u2013280 (2024).","journal-title":"Brain"},{"key":"51502_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich, M. T., Oertel, W. H., Surmeier, D. J. & Geibl, F. F. Mitochondrial dysfunction in Parkinson\u2019s disease\u2014a key disease hallmark with therapeutic potential. Mol. Neurodegen. 18, 83 (2023).","journal-title":"Mol. Neurodegen."},{"key":"51502_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106343","volume":"188","author":"M Toffoli","year":"2023","unstructured":"Toffoli, M. et al. Phenotypic effect of GBA1 variants in individuals with and without Parkinson\u2019s disease: the RAPSODI study. Neurobiol. Dis. 188, 106343 (2023).","journal-title":"Neurobiol. Dis."},{"key":"51502_CR14","doi-asserted-by":"publisher","unstructured":"Geibl, F. F. et al. \u03b1-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson\u2019s disease. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.12.11.571045 (2023).","DOI":"10.1101\/2023.12.11.571045"},{"key":"51502_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fneur.2015.00123","volume":"6","author":"JJ Fraigne","year":"2015","unstructured":"Fraigne, J. J., Torontali, Z. A., Snow, M. B. & Peever, J. H. REM sleep at its core\u2014 circuits, neurotransmitters, and pathophysiology. Front. Neurol. 6, 123 (2015).","journal-title":"Front. Neurol."},{"key":"51502_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek, K. et al. The Parkinson\u2019s progression markers initiative (PPMI)\u2014establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5, 1460\u20131477 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"51502_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41586-021-04059-0","volume":"599","author":"P Gonz\u00e1lez-Rodr\u00edguez","year":"2021","unstructured":"Gonz\u00e1lez-Rodr\u00edguez, P. et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature 599, 650\u2013656 (2021).","journal-title":"Nature"},{"key":"51502_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/mds.28260","volume":"36","author":"RV Kogan","year":"2021","unstructured":"Kogan, R. V. et al. Four-year follow-up of [18F] fluorodeoxyglucose positron emission tomography-based Parkinson\u2019s disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression. Mov. Disord. 36, 230\u2013235 (2021).","journal-title":"Mov. Disord."},{"key":"51502_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/mds.28859","volume":"37","author":"A Janzen","year":"2022","unstructured":"Janzen, A. et al. Rapid eye movement sleep behavior disorder: abnormal cardiac image and progressive abnormal metabolic brain pattern. Mov. Disord. 37, 624\u2013629 (2022).","journal-title":"Mov. Disord."},{"key":"51502_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-022-00753-3","volume":"19","author":"M Perovnik","year":"2023","unstructured":"Perovnik, M., Rus, T., Schindlbeck, K. A. & Eidelberg, D. Functional brain networks in the evaluation of patients with neurodegenerative disorders. Nat. Rev. Neurol. 19, 73\u201390 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"51502_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","volume":"20","author":"MG Miglis","year":"2021","unstructured":"Miglis, M. G. et al. Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 20, 671\u2013684 (2021).","journal-title":"Lancet Neurol."},{"key":"51502_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95255-5","volume":"11","author":"GC Churchill","year":"2021","unstructured":"Churchill, G. C. et al. Acetylation turns leucine into a drug by membrane transporter switching. Sci. Rep. 11, 15812 (2021).","journal-title":"Sci. Rep."},{"key":"51502_CR23","doi-asserted-by":"publisher","first-page":"9249","DOI":"10.1038\/s41598-021-88693-8","volume":"11","author":"N Hegdekar","year":"2021","unstructured":"Hegdekar, N., Lipinski, M. M. & Sarkar, C. N-Acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice. Sci. Rep. 11, 9249 (2021).","journal-title":"Sci. Rep."},{"key":"51502_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1046\/j.0953-816x.2000.01447.x","volume":"13","author":"N Vibert","year":"2001","unstructured":"Vibert, N. & Vidal, P. P. In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur. J. Neurosci. 13, 735\u2013748 (2001).","journal-title":"Eur. J. Neurosci."},{"key":"51502_CR25","doi-asserted-by":"publisher","first-page":"e0229585","DOI":"10.1371\/journal.pone.0229585","volume":"15","author":"GC Churchill","year":"2020","unstructured":"Churchill, G. C., Strupp, M., Galone, A. & Platt, F. M. Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance. PLoS ONE 15, e0229585 (2020).","journal-title":"PLoS ONE"},{"key":"51502_CR26","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","volume":"146","author":"MJ Sateia","year":"2014","unstructured":"Sateia, M. J. International classification of sleep disorders-third edition: highlights and modifications. Chest 146, 1387\u20131394 (2014).","journal-title":"Chest"},{"key":"51502_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/sleep\/31.5.717","volume":"31","author":"T Miyamoto","year":"2008","unstructured":"Miyamoto, T. et al. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 31, 717\u2013723 (2008).","journal-title":"Sleep"},{"key":"51502_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/chemse\/22.1.39","volume":"22","author":"T Hummel","year":"1997","unstructured":"Hummel, T., Sekinger, B., Wolf, S. R., Pauli, E. & Kobal, G. \u2018Sniffin\u2019 sticks\u2019: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem. Senses 22, 39\u201352 (1997).","journal-title":"Chem. Senses"},{"key":"51502_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s004050050223","volume":"257","author":"G Kobal","year":"2000","unstructured":"Kobal, G. et al. Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. Eur. Arch. Otorhinolaryngol. 257, 205\u2013211 (2000).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"51502_CR30","doi-asserted-by":"crossref","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov. Disord. 18, 738\u2013750 (2003).","DOI":"10.1002\/mds.10473"},{"key":"51502_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"51502_CR32","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/mds.23079","volume":"25","author":"J-F Gagnon","year":"2010","unstructured":"Gagnon, J.-F., Postuma, R. B., Joncas, S., Desjardins, C. & Latreille, V. The Montreal Cognitive Assessment: a screening tool for mild cognitive impairment in REM sleep behavior disorder. Mov. Disord. 25, 936\u2013940 (2010).","journal-title":"Mov. Disord."},{"key":"51502_CR33","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","volume":"19","author":"M Visser","year":"2004","unstructured":"Visser, M., Marinus, J., Stiggelbout, A. M. & van Hilten, J. J. Assessment of autonomic dysfunction in Parkinson\u2019s disease: the SCOPA-AUT. Mov. Disord. 19, 1306\u20131312 (2004).","journal-title":"Mov. Disord."},{"key":"51502_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670\u2013676 (2008).","journal-title":"Neurology"},{"key":"51502_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"51502_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12759","volume":"71","author":"D Kunz","year":"2021","unstructured":"Kunz, D., Stotz, S. & Bes, F. Treatment of isolated REM sleep behavior disorder using melatonin as a chronobiotic. J. Pineal Res. 71, e12759 (2021).","journal-title":"J. Pineal Res."},{"key":"51502_CR37","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/mds.27094","volume":"32","author":"SK Meles","year":"2017","unstructured":"Meles, S. K. et al. FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder. Mov. Disord. 32, 1482\u20131486 (2017).","journal-title":"Mov. Disord."},{"key":"51502_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","volume":"133","author":"K Doppler","year":"2017","unstructured":"Doppler, K. et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson\u2019s disease. Acta Neuropathol. 133, 535\u2013545 (2017).","journal-title":"Acta Neuropathol."},{"key":"51502_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0436-y","volume":"8","author":"SM Adriaanse","year":"2018","unstructured":"Adriaanse, S. M. et al. Clinical evaluation of (123)IFP-CIT SPECT scans on the novel brain-dedicated InSPira HD SPECT system: a head-to-head comparison. EJNMMI Res. 8, 85 (2018).","journal-title":"EJNMMI Res."},{"key":"51502_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12021-014-9235-4","volume":"12","author":"PA Della Rosa","year":"2014","unstructured":"Della Rosa, P. A. et al. A standardized 18F-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 12, 575\u2013593 (2014).","journal-title":"Neuroinformatics"},{"key":"51502_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.nicl.2014.06.007","volume":"5","author":"LK Teune","year":"2014","unstructured":"Teune, L. K. et al. Parkinson\u2019s disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. NeuroImage Clin. 5, 240\u2013244 (2014).","journal-title":"NeuroImage Clin."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51502-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T07:07:35Z","timestamp":1725260855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51502"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51502-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wolfgang H. Oertel has received speaker\u2019s honoria on educational symposia sponsored by Abbvie, the International Movement Disorders Society and Stada Pharma. He acts as a consultant for Lario Therapeutics and is a member of advisory boards with Intrabio and MODAG. He holds stock options with Intrabio related to this manuscript and stock options with MODAG unrelated to this work. The institution of W.H.O., not W.H.O personally received\/s scientific grants from the German Research Foundation, the Michael J Fox Foundation and Rittal Foundation unrelated to the manuscript. Jan Booij is a consultant of GE Healthcare. The institution of J.B., not J.B. personally received research funding from GE Healthcare. Lars Timmermann has received speaker\u2019s honoria on educational symposia sponsored by Abbvie, Boston Scientific, DIAPLAN, Neuraxpharm, Novartis, the International Movement Disorders Society und Teva. He has been a consultant for Boston Scientific. The institution of L.T., not L.T. personally received\/s funding by Boston Scientific, the German Research Foundation, the German Ministry of Education and Research, the Otto-Loewi-Foundation and the Deutsche Parkinson Vereinigung. Neither L.T. nor any member of his family holds stocks, stock options, patents or financial interests in any of the above-mentioned companies or their competitors. Michael Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker\u2019s honoraria on educational symposia sponsored by Abbott, Auris Medical, Biogen, Eisai, Gr\u00fcnenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris. He acts as a consultant for Abbott, AurisMedical, Bulbitec, Heel, IntraBio, Sensorion and Vertify. He is an investor and share-holder of IntraBio. The institution of M.S., not M.S. personally received\/s support for clinical studies from Decibel, USA, Cure within Reach, USA and Heel, Germany. He distributes \u201cM-glasses\u201d and \u201cPositional vertigo App\u201d. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7619"}}